• Peter Propping
Part of the Reviews of Physiology, Biochemistry and Pharmacology book series (volume 83)


Twin Pair Twin Study Identical Twin Malignant Hyperthermia Slow Acetylators 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agarwal, D.P., Srivastava, L.M., Goedde, H.W.: A note on suxamethonium sensitivity and serum cholinesterase variants. Hum. Genet. 32, 85–88 (1976)Google Scholar
  2. Akiskal, H.S., McKinney, W.T.: Overview of recent research in depression. Arch. Gen. Psychiat. 32, 285–305 (1975)Google Scholar
  3. Alexanderson, B.: Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and multiple oral doses — a cross-over study. Eur. J. Clin. Pharmacol. 5, 1–10 (1972)Google Scholar
  4. Alexanderson, B., Borga, O.: Interindividual differences in plasma protein binding of nortriptyline in man — a twin study. Eur. J. Clin. Pharmacol. 4, 196–200 (1972)Google Scholar
  5. Alexanderson, B., Evans, D.A.P., Sjöqvist, F.: Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Brit. Med. J. 4, 764–768 (1969)Google Scholar
  6. Altland, K.: Pseudocholinesterasen. In: Humangenetik. Ein kurzes Handbuch in fünf Bänden. Becker, P.E. (ed.). Stuttgart: Thieme 1975, Vol. I/3, p. 327–351Google Scholar
  7. Altland, K., Goedde, H.W.: Heterogeneity in the silent gene phenotype of pseudocholinesterase of human serum. Biochem. Genet. 4, 321–338 (1970)Google Scholar
  8. Andreasen, P.B., Frøland, A., Skovsted, L., Andersen, S.A., Hauge, M.: Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: the role of genetic factors. Acta Med. Scand. 193, 561–564 (1973)Google Scholar
  9. Angst, J.: A clinical analysis of the effects of tofranil in depression. Longitudinal and follow-up studies. Treatment of blood-relations. Psychopharmacologia 2, 381–407 (1961)Google Scholar
  10. Angst, J.: Antidepressiver Effekt und genetische Faktoren. Arzneim. Forsch. 14, 496–500 (1964)Google Scholar
  11. Armaly, M.F.: Genetic factors related to glaucoma. Ann. N.Y. Acad. Sci. 151, 861–875 (1968)Google Scholar
  12. Asberg, M.: Plasma nortriptyline levels — relationship to clinical effects. Clin. Pharmacol. Ther. 16, 215–229 (1974)Google Scholar
  13. Asberg, M., Evans, D.A.P., Sjöqvist, F.: Genetic control of nortriptyline plasma levels in man: a study of the relatives of propositi with high plasma concentration. J. Med. Genet. 8, 129–135 (1971)Google Scholar
  14. Asmussen, E., Hald, J., Larsen, V.: The pharmacological action of acetaldehyde on the human organism. Acta Pharmacol. 4, 311–320 (1948)Google Scholar
  15. Atlas, S.A., Vesell, E.S., Nebert, D.W.: Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes. Cancer Res. 36, 4619–4630 (1976)Google Scholar
  16. Baker, E.L., Smrek, A., Kimbrough, R.D., Hudgins, M., Landrigan, P.J., Liddle, J.A.: Hereditary cholinesterase deficiency: a report of a family with two rare genotypes. Clin. Genet. 12, 134–138 (1977)Google Scholar
  17. Bennion, L.J., Li, T.-K.: Alcohol metabolism in American Indians and Whites. N. Engl. J. Med. 294, 9–13 (1976)Google Scholar
  18. Bente, D.: Differentielle und generelle Wirkungen psychotroper Pharmaka auf das menschliche EEG. In: Psychopharmacology, Sexual Disorders and Drug Abuse. Ban, T.A., et al. (eds.). Amsterdam: North-Holland 1973, p. 149–156Google Scholar
  19. Beutler, E.: Glucose 6-phosphate dehydrogenase deficiency. In: The Metabolic Basis of Inherited Disease. Stanbury, J.B., Wyngaarden, J.B., Fredrickson, D.S. (eds.). New York: McGraw-Hill, p. 1358–1388Google Scholar
  20. Bönicke, R., Lisboa, B.P.: Über die Erbbedingtheit der intraindividuellen Konstanz der Isoniazidausscheidung. Naturwissenschaften 44, 314 (1957)Google Scholar
  21. Brewer, G.J.: Human ecology, an expanding role for the human geneticist. Am. J. Hum. Genet. 23, 92–94 (1971)Google Scholar
  22. Campbell, W., Tilstone, W.J., Lawson, D.H., Hutton, I., Lawrie, T.D.V.: Acetylator phenotype and the clinical pharmacology of slow-release procainamide. Br. J. Clin. Pharmacol. 3, 1023–1026 (1976)Google Scholar
  23. Carlson, H.B., Anthony, E.M., Russell, W.F., Middlebrook, G.: Prophylaxis of isoniazid neuropathy with pyridoxine. N. Engl. J. Med. 255, 118–122 (1956)Google Scholar
  24. Cascorbi, H.F., Vesell, E.S., Blake, D.A., Helrich, M.: Genetic and environmental influence on halothane metabolism in twins. Clin. Pharmacol. Ther. 12, 50–55 (1971)Google Scholar
  25. Casper, R.C., Pandey, G., Gosenfeld, L., Davis, J.M.: Intracellular lithium and clinical response. Lancet 1976/II, 418–419Google Scholar
  26. Caspers, H.: Die Beeinflussung der corticalen Krampferregbarkeit durch das aufsteigende Reticulärsystem des Hirnstammes. I. Reizwirkungen. Z. Ges. Exp. Med. 129, 128–144 (1957)Google Scholar
  27. Caspers, H.: Die Beeinflussung der corticalen Krampferregbarkeit durch das aufsteigende Reticulärsystem des Hirnstammes. II. Narkosewirkungen. Z. Ges. Exp. Med. 129, 582–600 (1958)Google Scholar
  28. Claridge, G., Canter, S., Hume, W.J.: Personality Differences and Biological Variations. A Study of Twins. Oxford: Pergamon Press 1973Google Scholar
  29. Cunningham, J.L., Bullen, M.F., Evans, D.A.P.: The pharmacokinetics of acetanilide and of diphenylhydantoin sodium. Eur. J. Clin. Pharmacol. 7, 461–466 (1974)Google Scholar
  30. Das, P.K.: Further evidence on the heterogeneity of 'silent’ serum cholinesterase variants. Hum. Hered. 23, 88–96 (1973)Google Scholar
  31. Dengler, H.J., Eichelbaum, M.: Polymorphismen und Defekte des Arzneimittelstoff-wechsels als Ursache toxischer Reaktionen. Arzneim. Forsch. 27, 1836–1844 (1977)Google Scholar
  32. Desforges, J.F.: Genetic implications of G-6-PD deficiency. N. Engl. J. Med. 294, 1438–1440 (1976)Google Scholar
  33. Dorus, E., Pandey, G.N., Davis, J.M.: Genetic determinant of lithium ion distribution. Arch. Gen. Psychiat. 32, 1097–1102 (1975)Google Scholar
  34. Dorus, E., Pandey, G.N., Frazer, A., Mendels, J.: Genetic determinant of lithium ion distribution. I. An in vitro monozygotic-dizygotic twin study. Arch. Gen. Phychiat. 31, 463–465 (1974)Google Scholar
  35. Drayer, D.E., Reidenberg, M.M.: Clinical consequences of polymorphic acetylation of basic drugs. Clin. Pharmacol. Ther. 22, 251–258 (1977)Google Scholar
  36. Drummond, D.: Rats resistant to warfarin. New Sci. 30, 771–772 (1966)Google Scholar
  37. Edwards, J.A., Evans, D.A.P.: Ethanol metabolism in subjects possessing typical and atypical liver alcohol dehydrogenase. Clin. Pharmacol. Ther. 8, 824–829 (1967)Google Scholar
  38. Eidus, L., Harnanansingh, M.T.: A more sensitive spectrophotometric method for determination of isoniazid in serum or plasma. Clin. Chem. 17, 492–494 (1971)Google Scholar
  39. Ellard, G.A., Gammon, P.T.: Pharmacokinetics of isoniazid metabolism in man. J. Pharmacokinet. Biopharm. 4, 83–113 (1976)Google Scholar
  40. Emery, A.E.H., Anand, R., Danford, N., Duncan, W.: Aryl-hydrocarbon-hydroxylase inducibility in patients with lung cancer. Lancet 1978/I, 470–472Google Scholar
  41. Endrenyi, L., Inaba, T., Kalow, W.: Genetic study of amobarbital elimination based on its kinetics in twins. Clin. Pharmacol. Ther. 20, 701–714 (1976)Google Scholar
  42. Evans, D.A.P.: An improved and simplified method of detecting the acetylator phenotype. J. Med. Genet. 6, 405–407 (1969)Google Scholar
  43. Evans, D.A.P., Davidson, K., Pratt, R.T.C.: The influence of acetylator phenotype on the effect of treating depression with phenelzine. Clin. Pharmacol. Ther. 6, 430–435 (1965)Google Scholar
  44. Evans, D.A.P., Manley, K., McKusick, V.A.: Genetic control of isoniazid metabolism in man. Brit. Med. J. 2, 485–491 (1960)Google Scholar
  45. Evans, D.A.P., White, T.A.: Human acetylation polymorphism. J. Lab. Clin. Med. 63, 394–403 (1964)Google Scholar
  46. Ewing, J.A., Rouse, B.A., Pellizzari, E.D.: Alcohol sensitivity and ethnic background. Am. J. Psychiat. 131, 206–210 (1974)Google Scholar
  47. Farris, J.J., Jones, B.M.: Ethanol metabolism in male American Indians and Whites. Alcoholism. Clin. Exp. Res. 2, 77–81 (1978)Google Scholar
  48. Fenna, D., Mix, L., Schaefer, O., Gilbert, J.A.L.: Ethanol metabolism in various racial groups. Can. Med. Assoc. J. 105, 472–475 (1971)Google Scholar
  49. Flatz, G., Xirotiris, N.: Glukose-6-Phosphat-Dehydrogenase. In: Humangenetik. Ein kurzes Handbuch in fünf Bänden. Becker, P.E. (ed.). Stuttgart: Thieme 1975, Vol. I/3, p. 494–535Google Scholar
  50. Freese, E., Sklarow, S., Freese, E.B.: DNA damage caused by antidepressant hydrazines and related drugs. Mutat. Res. 5, 343–348 (1968)Google Scholar
  51. Fukui, M., Wakasugi, C.: Liver alcohol dehydrogenase in a Japanese population. Jap. J. Leg. Med. 26, 46–51 (1972)Google Scholar
  52. Furst, D.E., Gupta, N., Paulus, H.E.: Salicylate metabolism in twins. Evidence suggesting a genetic influence and induction of salicylate formation. J. Clin. Invest. 60, 32–42 (1977)Google Scholar
  53. Garry, P.J., Dietz, A.A., Lubrano, T., Ford, P.C., James, K., Rubinstein, H.M.: New allele at cholinesterase locus 1. J. Med. Genet. 13, 38–42 (1976)Google Scholar
  54. Gelber, R., Peters, J.H., Gordon, G.R., Glazko, A.J., Levy, L.: The polymorphic acetylation of dapsone in man. Clin. Pharmacol. Ther. 12, 225–238 (1971)Google Scholar
  55. Geldmacher-v. Mallinckrodt, M., Lindorf, H.H., Petenyi, M., Flügel, M., Fischer, T., Hiller, T.: Genetisch determinierter Polymorphismus der menschlichen Serum-Para-oxonase(ED Humangenetik 17, 331–335 (1973)Google Scholar
  56. Goedde, H.W.: Pseudocholinesterase variation. Internat. Titisee Conference, Oct. 13–15, 1977. Hum. Genet. (in press)Google Scholar
  57. Goedde, H.W., Airland, K., Schloot, W. (eds.): Pharmacogenetics. Hum. Genet. 9, 197–280 (1970)Google Scholar
  58. Goedde, H.W., Doenicke, A., Altland, K.: Pseudocholinesterasen. Berlin-Heidelberg-New York: Springer 1967Google Scholar
  59. Goedde, H.W., Löhr, G.W., Waller, H.D.: Ergebnisse und Probleme der Pharmakogenetik. Arzneim. Forsch. 15, 1460–1468 (1965)Google Scholar
  60. Goldsmith, R.J., Rothhammer, F., Schull, W.J.: Mydriasis and heredity. Clin. Genet. 12, 129–133 (1977)Google Scholar
  61. Grafe, A., Lorenz, R., Vollmar, J.: Testing the mutagenic potency of chemical substances in a linear host-mediated assay. Mutat. Res. 31, 205–216 (1975)Google Scholar
  62. Greil, W., Eisenried, F., Becker, B.F., Duhm, J.: Interindividual differences in the Na+-dependent Li+ countertransport system and in the Li+ distribution ratio across the red cell membrane among Li+-treated patients. Psychopharmacol. 53, 19–26 (1977)Google Scholar
  63. Gutsche, B.B., Scott, E.M., Wright, R.C.: Hereditary deficiency of pseudocholinesterase in Eskimos. Nature 215, 322–323 (1967)Google Scholar
  64. Hanna, J.M.: Metabolic responses of Chinese, Japanese and Europeans to alcohol. Alcoholism. Clin. Exp. Res. 2, 89–92 (1978)Google Scholar
  65. Harada, S., Agarwal, D.P., Goedde, H.W.: Human liver alcohol dehydrogenase isoenzyme variations. Hum. Genet. 40, 215–220 (1978)Google Scholar
  66. Harris, C.C., Autrup, H., Connor, R., Barrett, L.A., McDowell, E.M., Trump, B.F.: Interindividual variation in binding of benzo(a)pyrene to DNA in cultured human bronchi. Science 194, 1067–1069 (1976)Google Scholar
  67. Harris, H., Hopkinson, D.A.: Average heterozygosity per locus in man: an estimate based on the incidence of enzyme polymorphisms. Ann. Hum. Genet. 36, 9–20 (1972)PubMedGoogle Scholar
  68. Heuschert, D.: EEG-Untersuchungen an eineiigen Zwillingen in höherem Lebensalter. Z. Menschl. Vererb. Konstitut.-Lehre 37, 128–172 (1963)Google Scholar
  69. Hoo, J.-J., Hussein, L., Goedde, H.W.: A simplified micromethod for the determination of the acetylator phenotype. J. Clin. Chem. Clin. Biochem. 15, 329–332 (1977)Google Scholar
  70. Hughes, H.B., Biehl, J.P., Jones, A.P., Schmidt, L.H.: Metabolism of isoniazid in man as related to occurrence of peripheral neuritis. Am. Rev. Tuberc. 70, 266–273 (1954)Google Scholar
  71. Idle, J.R., Mahgoub, A., Lancaster, R., Smith, R.L.: Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci. 22, 979–984 (1978)Google Scholar
  72. Itil, T.: Quantitative pharmaco-electroencephalography. Use of computerized cerebral biopotentials in psychotropic drug research. In: Psychotropic Drugs and the Human EEG. Itil, T.M. (ed.). Basel: Karger 1974, p. 43–75Google Scholar
  73. Jenne, J.W., Orser, M.: Partial purification and properties of the isoniazid trans-acetylase in the human liver. Its relationship to the acetylation of p-aminosalicylic acid. J. Clin. Invest. 44, 1992–2002 (1965)Google Scholar
  74. Jessamine, A.G., Hodghkin, M.M., Eidus, L.: Urine tests for phenotyping slow and fast acetylators. Can. J. Public Health 65, 119–123 (1974)Google Scholar
  75. Jinks, J.L., Fulker, D.W.: Comparison of the biometrical, genetical, MAVA and classical approaches to the analysis of human behaviour. Psychol. Bull. 73, 311–349 (1970)Google Scholar
  76. Johnston, F.E., Blumberg, B.S., Agarwal, S.S., Melartin, L., Burch, T.A.: Alloalbuminemia in southwestern U.S. Indians. Polymorphism of albumin Naskapi and albumin Mexico. Hum. Biol. 41, 263–270 (1969)Google Scholar
  77. Johnstone, E.C.: The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine. Psychopharmacology 46, 289–294 (1976)Google Scholar
  78. Johnstone, E., Marsh, W.: Acetylator status and response to phenelzine in depressed patients. Lancet 1973/I, 567–570 (1973)Google Scholar
  79. Juel-Nielsen, N., Harvald, B.: The electroencephalogram in uniovular twins brought up apart. Acta Genet. Statist. Med. 8, 57–64 (1958)Google Scholar
  80. Kahn, A.: G6PD variants. Internat. Titisee Conference, Oct. 13–15, 1977. Hum. Genet. (in press)Google Scholar
  81. Kalow, W.: Pharmacogenetics. Heredity and the Response to Drugs. Philadelphia: Saunders 1962Google Scholar
  82. Kalow, W.: Succinylcholine and malignant hyperthermia. Fed. Proc. 31, 1270–1275 (1972)Google Scholar
  83. Kalow, W., Britt, B.A., Richter, A.: The caffeine test of isolated human muscle in relation to malignant hyperthermia. Can. Anaesth. Soc. J. 24, 678–694 (1977a)Google Scholar
  84. Kalow, W., Kadar, D., Inaba, T., Tang, B.K.: Case of deficiency of N-hydroxylation of amobarbital. Clin. Pharmacol. Ther. 21, 530–535 (1977 b)Google Scholar
  85. Karim, A.K.M.B., Evans, D.A.P.: Polymorphic acetylation of nitrazepam. J. Med. Genet. 13, 17–19 (1976)Google Scholar
  86. Karlsson, E., Aberg, G., Collste, P., Molin, L., Norlander, B., Sjöqvist, F.: Acetylation of procaine amide in man. A preliminary communication. Eur. J. Clin. Pharmacol. 8, 79–81 (1975)Google Scholar
  87. Kellermann, G., Luyten-Kellermann, M., Shaw, C.R.: Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am. J. Hum. Genet. 25, 327–331 (1973a)Google Scholar
  88. Kellermann, G., Shaw, C.R., Luyten-Kellermann, M.: Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. N. Engl. J. Med. 289, 934–937 (1973b)Google Scholar
  89. Kimball, R.F.: The mutagenicity of hydrazine and some of its derivatives. Mutat. Res. 39, 111–126 (1977)Google Scholar
  90. Kirkman, H.N.: Glucose-6-phosphate dehydrogenase. Adv. Hum. Genet. 2, 1–60 (1971)Google Scholar
  91. Klein, H., Fahrig, H., Wolf, H.P.: Die Bestimmung der Alkoholdehydrogenase-und Glutaminsäure-Oxalessigsäure-Transaminase-Aktivität der menschlichen Leber nach dem Tode. Dtsch. Z. Ges. Gerichtl. Med. 52, 615–629 (1962)Google Scholar
  92. Knight, R.A., Selin, J., Harris, H.W.: Genetic factors influencing isoniazid blood levels in humans. In: Transactions of Conference on Chemotherapy of Tuberculosis, 18th Conf. 1959, p. 52–58Google Scholar
  93. Knorring, L. v., Oreland, L., Perris, C., Wiberg, A.: Evaluation of the lithium RBC/plasma ratio as a predictor of the prophylactic effect of lithium treatment in affective disorders. Pharmakopsychiatr. 9, 81–84 (1976)Google Scholar
  94. Koch-Weser, J.: Drug therapy: hydralazine. N. Engl. J. Med. 295, 320–323 (1976)Google Scholar
  95. Koch-Weser, J.: Serum procainamide levels as therapeutic guides. Clin. Pharmacokinet. 2, 389–402 (1977)Google Scholar
  96. Kopun, M., Propping, P.: The kinetics of ethanol absorption and elimination in twins and supplementary repetitive experiments in singleton subjects. Eur. J. Clin. Pharmacol. 11, 337–344 (1977)Google Scholar
  97. Koukkou, M., Lehmann, D.: Human EEG spectra before and during cannabis hallucinations. Biol. Psychiat. 11, 663–677 (1976)Google Scholar
  98. Kutt, H.: Biochemical and genetic factors regulating dilantin metabolism in man. Ann. N.Y. Acad. Sci. 179, 704–722 (1971)Google Scholar
  99. Kutt, H., Wolk, M., Scherman, R., McDowell, F.: Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 14, 542–548 (1964)PubMedGoogle Scholar
  100. La Du, B.N.: Isoniazid and pseudocholinesterase polymorphisms. Fed. Proc. 31, 1276–1285 (1972)Google Scholar
  101. La Du, B.N., Kalow, W.: Pharmacogenetics. Ann. N.Y. Acad. Sci. 151, Art. 2, 691–1001 (1968)Google Scholar
  102. Langenbeck, U.: Albumin. In: Humangenetik. Ein kurzes Handbuch in fünf Bänden. Becker, P.E. (ed.). Stuttgart: Thieme 1975, Vol. I/3, p. 1–34Google Scholar
  103. Lenz, F.: Inwieweit kann man aus Zwillingsbefunden auf Erbbedingtheit und Umwelteinfluß schließen? Dtsch. Med. Wschr. 61, 873–875 (1935)Google Scholar
  104. Lewis, R.J., Spivack, M., Spaet, T.H.: Warfarin resistance. Am. J. Med. 42, 620 (1967)Google Scholar
  105. Lüth, K.-F.: Untersuchungen über die Alkoholblutkonzentration nach Alkoholgaben bei 10 eineiigen und 10 zweieiigen Zwillingspaaren. Dtsch. Z. Gerichtl. Med. 32, 145–164 (1939)Google Scholar
  106. Luzzatto, L.: New developments in glucose-6-phosphate dehydrogenase deficiency. Isr. J. Med. Sci. 9, 1484–1498 (1973)Google Scholar
  107. Luzzatto, L.: Inherited haemolytic states: glucose-6-phosphate dehydrogenase deficiency. Clin. Haematol. 4, 83–108 (1975)Google Scholar
  108. Mahgoub, A., Idle, J.R., Dring, L.G., Smith, R.L.: Polymorphic hydroxylation of de-brisoquine in man. Lancet 1977/II, 584–586Google Scholar
  109. Mattila, M.J., Tiitinen. H., Alhava, E.: Acetylation pattern of different sulphonamides in rapid and slow isoniazid inactivators. Ann. Med. Exp. Fenn. 47, 308–315 (1969)Google Scholar
  110. Melartin, L.: Albumin polymorphism in man. Studies on albumin variants in North American native populations. Acta Pathol. Microbiol. Scand. (Suppl.) 191, 1–50 (1967)Google Scholar
  111. Mendels, J., Frazer, A.: Intracellular lithium concentration and clinical response: towards a membrane theory of depression. J. Psychiatr. Res. 10, 9–18 (1973)Google Scholar
  112. Mendels, J., Frazer, A., Baron, J., Kukopulos, A., Reginaldi, D., Tondo, L., Caliari, B.: Intra-erythrocyte lithium ion concentration and long-term maintenance treatment. Lancet 1976/I, 966Google Scholar
  113. Mendlewicz, J., Fieve, R., Stallone, F.: Relationship between the effectiveness of lithium therapy and family history. Am. J. Psychiat. 130, 1011–1013 (1973)Google Scholar
  114. Mitchell, J.R., Thorgeirson, U.P., Black, M., Timbrell, J.A., Snodgrass, W.R., Potter, W.Z., Jollow, D.J., Keiser, H.R.: Increased incidence of isoniazid hepatitis in rapid acetylators — possible relation to hydrazine metabolites. Clin. Pharmacol. Ther. 18, 70–79 (1975)Google Scholar
  115. Motulsky, A.G. (ed.): Pharmacogenetics and ecogenetics. Internat. Titisee Conference, Oct. 13–15, 1977. Hum. Genet. (in press)Google Scholar
  116. Müller-Oerlinghausen, B.: Bedeutung der Pharmakokinetik für die Therapie mit Anti-depressiva. Pharmakopsychiat. 11, 55–62 (1978)Google Scholar
  117. Naito, S.-F., Nelson, E.: Acetylation of sulfamethylthiodiazole. J. Pharm. Sci. 52, 707 (1963)Google Scholar
  118. Omenn, G.S., Motulsky, A.G.: Psychopharmacogenetics. In: Human Behavior Genetics. Kaplan, A.R. (ed.). Springfield (Ill.): Charles C. Thomas 1976, p. 363–384Google Scholar
  119. O'Reilly, R.A.: The second reported kindred with hereditary resistance to oral anticoagulant drugs. N. Engl. J. Med. 282, 1448–1451 (1970)Google Scholar
  120. O'Reilly, R.A.: Genetic factors in the response to oral anticoagulant drugs. Proc. 4th Int. Congr. Hum. Genet. (Paris), Sept. 6–11, 1971. Excerpta Med. Int. Congr. Ser. No. 250, 428–442 (1972)Google Scholar
  121. O'Reilly, R.A., Aggeler, P.M., Hoag, M.S., Leong. L.S., Kropatkin, M.L.: Hereditary transmission of exceptional resistance to coumarin anti-coagulant drugs. The first reported kindred. N. Engl. J. Med. 271, 809–815 (1964)Google Scholar
  122. Paigen, B., Gurtoo, H.L., Minowada, J., Houten, L., Vincent, R., Paigen, K., Bejba Parker, N., Ward, E., Thompson Hayner, N.: Questionable relation of aryl hydrocarbon hydroxylase to lung-cancer risk. N. Engl. J. Med. 297, 346–350 (1977)Google Scholar
  123. Pandey, G.N., Ostrow, D.G., Haas, M., Doras, E., Casper, R.C., Davis, J.M.: Abnormal lithium and sodium transport in erythrocytes of a manic patient and some members of his family. Proc. Natl. Acad. Sci. USA 74, 3607–3611 (1977)Google Scholar
  124. Pare, C.M.B., Mack, J.W.: Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J. Med. Genet. 8, 306–309 (1971)Google Scholar
  125. Pare, C.M.B., Rees, L., Sainsbury, M.J.: Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet 1962/II, 1340–1343Google Scholar
  126. Perry, H.M., Tan, E.M., Carmody, S., Sakamoto, A.: Relationship of acetyltransferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J. Lab. Clin. Med. 76, 114–125 (1970)Google Scholar
  127. Piafsky, K.M., Borga, O.: Plasma protein binding of basic drugs. II. Importance of α1-acid glycoprotein for interindividual variation. Clin. Pharmacol. Ther. 22, 545–549 (1977)Google Scholar
  128. Playfer, J.R., Eze, L.C., Bullen, M.F., Evans, D.A.P.: Genetic polymorphism and inter-ethnic variability of plasma paroxonase activity. J. Med. Genet. 13, 337–342 (1976)Google Scholar
  129. Pool, J.G., O'Reilly, R.A., Schneidermann, L.J., Alexander, M.: Warfarin resistance in the rat. Am. J. Physiol. 215, 627–631 (1968)Google Scholar
  130. Propping, P.: Genetic control of ethanol action on the central nervous system. An EEG study in twins. Hum. Genet. 35, 309–334 (1977)Google Scholar
  131. Propping, P., Kopun, M.: Pharmacogenetic aspects of psychoactive drugs: Facts and fancy. Hum. Genet. 20, 291–320 (1973)Google Scholar
  132. Reed, T.E., Kalant, H., Gibbins, R.J., Kapur, B.M., Rankin, J.G.: Alcohol and acetal-dehyde metabolism in Caucasians, Chinese and Amerinds. Can. Med. Assoc. J. 115, 851–855 (1976)Google Scholar
  133. Reidenberg, M.M.: Acetylation polymorphism in man. Internat. Titisee Conference, Oct. 13–15, 1977. Hum. Genet. (in press)Google Scholar
  134. Reidenberg, M.M., Drayer, D., DeMarco, A.L., Bello, C.T.: Hydralazine elimination in man. Clin. Pharmacol. Ther. 14, 970–977 (1973)Google Scholar
  135. Reidenberg, M.M., Drayer, D.E., Levy, M., Warner, H.: Polymorphic acetylation of procainamide in man. Clin. Pharmacol. Ther. 17, 722–730 (1975)Google Scholar
  136. Remmer, H., Hirschmann, J., Greiner, I.: Die Bedeutung von Kumulation und Elimination für die Dosierung von Phenytoin (Diphenylhydantoin). Dtsch. Med. Wschr. 94, 1265–1272 (1969)PubMedGoogle Scholar
  137. Röhrborn, G., Propping, P., Buselmaier, W.: Mutagenic activity of isoniazid and hydrazine in mammalian test systems. Mutat. Res. 16, 189–194 (1972)Google Scholar
  138. Rubinstein, H.M., Dietz, A.A., Lubrano, T.: E1k, another quantitative variant at cholinesterase locus 1. J. Med. Genet. 15, 27–29 (1978)Google Scholar
  139. Rüdiger, H.W., Kohl, F., Mangels, W., Wichert, P. v., Bartram, C.R., Wöhler, W., Passarge, E.: Benzpyrene induces sister chromatid exchanges in cultured human lymphocytes. Nature 262, 290–292 (1976)Google Scholar
  140. Rybakowski, J.: Pharmacogenetic aspect of red blood cell lithium index in manic-depressive psychosis. Biol. Psychiat. 12, 425–429 (1977)Google Scholar
  141. Rybakowski, J., Strzyzewski, W.: Red-blood-cell lithium index and long-term maintenance treatment. Lancet 1976/I, 1408–1409Google Scholar
  142. Sachsenheimer, W., Pai, E.F., Schulz, G.E., Schirmer, R.H.: Halothane binds in the adenine-specific niche of crystalline adenylate kinase. FEBS Lett. 79, 310–312 (1977)Google Scholar
  143. Sauter, A.M., Boss, D., Wartburg, J.-P. v.: Reevaluation of the disulfiram-alcohol reaction in man. J. Stud. Alcohol. 38, 1680–1695 (1977)Google Scholar
  144. Schloot, W., Blume, K.G., Goedde, H.W., Flatz, G., Bhaibulaya, M.: Studies on isoniazid conversion in Thailand. Hum. Genet. 4, 274–279 (1967)Google Scholar
  145. Schmitt, J., Schmidt, K., Ritter, H.: Hereditary malignant hyperpyrexia associated with muscle adenylate kinase deficiency. Hum. Genet. 24, 253–257 (1974)Google Scholar
  146. Schöneich, J.: Safety evaluation based on microbial assay procedure. Mutat. Res. 41, 89–94 (1976)Google Scholar
  147. Schönwald, A D., Bartram, C.R., Rüdiger, H.W.: Benzpyrene-induced sister chromatid exchanges in lymphocytes of patients with lung cancer. Hum. Genet. 36, 261–264 (1977)Google Scholar
  148. Schröder, H., Evans, D.A.P.: The polymorphic acetylation of sulphapyridine in man. J. Med. Genet. 9, 168–171 (1972)Google Scholar
  149. Schwartz, J.T., Reuling, F.H., Feinleib, M., Garrison, R.J., Collie, D.J.: Twin heritability study of the effect of corticosteroids on intraocular pressure. J. Med. Genet. 9, 137–143 (1972)Google Scholar
  150. Shahidi, N.T.: Acetophenetidin-induced methemoglobinemia. Ann. N. Acad. Sci. 151, 822–832 (1968)Google Scholar
  151. Smith, M., Hopkinson, D.A., Harris, H.: Developmental changes and polymorphism in human alcohol dehydrogenase. Ann. Hum. Genet. 34, 251–271 (1971)Google Scholar
  152. Stamatoyannopoulos, S., Chen, S.-H., Fukui, M.: Liver alcohol dehydrogenase in Japanese: High population frequency of atypical form and its possible role in alcohol sensitivity. Am. J. Hum. Genet. 27, 789–796 (1975)Google Scholar
  153. Stanbury, J.B., Wyngaarden, J.B., Fredrickson, D.S.: The Metabolic Basis of Inherited Disease. New York: McGraw Hill 1972Google Scholar
  154. Steegmüller, H.: Geographical distribution of pseudocholinesterase variants. Hum. Genet. 26, 167–185 (1975)Google Scholar
  155. Talseth, T.: Kinetics of hydralazine elimination. Clin. Pharmacol. Ther. 21, 715–720 (1977)Google Scholar
  156. Tang, B.K., Inaba, T., Kalow, W.: N-hydroxyamobarbital, the second major metabolite of amobarbital in man. Drug Metabl. Dispos. 3, 479–486 (1975)Google Scholar
  157. Timbrell, J.A., Wright, J.M., Baillie, T.: Monoacetylhydrazine as a metabolite of isoniazid in man. Clin. Pharmacol. Ther. 22, 602–608 (1977)Google Scholar
  158. Vesell, E.S. (ed.): Drug metabolism in man. Ann. N.Y. Acad. Sci. 179, 1–773 (1971)Google Scholar
  159. Vesell, E.S.: Advances in pharmacogenetics. Prog. Med. Genet. 9, 291–367 (1973)Google Scholar
  160. Vesell, E.S.: Twin studies in pharmacogenetics. Internat. Titisee Conference, Oct. 13–15, 1977. Hum. Genet. (in press)Google Scholar
  161. Vesell, E.S., Page, J.G.: Genetic control of drug levels in man: Antipyrine. Science 161, 72–73 (1968a)PubMedGoogle Scholar
  162. Vesell, E.S., Page, J.G.: Genetic control of drug levels in man: Phenylbutazone. Science 159, 1479–1480 (1968b)Google Scholar
  163. Vesell, E.S., Page, J.G.: Genetic control of dicoumarol levels in man. J. Clin. Invest. 47, 2657–2663 (1968c)Google Scholar
  164. Vesell, E.S., Page, J.G., Passananti, T.G.: Genetic and environmental factors affecting ethanol metabolism in man. Clin. Pharmacol. Ther. 12, 192–201 (1971)Google Scholar
  165. Vogel, F.: Moderne Probleme der Humangenetik. Ergebn. Inn. Med. Kinderheilk. 12, 52–125 (1959)Google Scholar
  166. Vogel, F.: The genetic basis of the normal human electroencephalogram (EEG). Hum. Genet. 10, 91–114 (1970)Google Scholar
  167. Wagner, J.G.: Intrasubject variation in elimination half-lives of drugs which are appreciably metabolized. J. Pharmacokinet. Biopharm. 1, 165–173 (1973)Google Scholar
  168. Wagner, J.G., Patel, J.A.: Variations in absorption and elimination rates of ethyl alcohol in a single subject. Res. Commun. Chem. Pathol. Pharmacol. 4, 61–76 (1972)Google Scholar
  169. Wartburg, J.P. v., Papenberg, J., Aebi, H.: An atypical human alcohol dehydrogenase. Can. J. Biochem. 43, 889–898 (1965)Google Scholar
  170. Wartburg, J.P. v., Schürch, P.M.: Atypical human liver alcohol dehydrogenase. Ann. N.Y. Acad. Sci. 151, 936–946 (1968)Google Scholar
  171. Weber, W.W., Cohen, S.N.: The mechanism of isoniazid acetylation by human N-ace-tyltransferase. Biochim. Biophys. Acta 151, 276–278 (1968)Google Scholar
  172. White, T.A., Evans, D.A.P.: The acetylation of sulfamethazine and sulfamethoxypyridazine by human subjects. Clin. Pharmacol. Ther. 9, 80–88 (1968)Google Scholar
  173. Whittaker, J.A., Evans, D.A.P.: Genetic control of phenylbutazone metabolism in man. Brit. Med. J. 4, 323–328 (1970)Google Scholar
  174. Wilding, G., Blumberg, B.S., Vesell, E.S.: Reduced warfarin binding of albumin variants. Science 195, 991–994 (1977)Google Scholar
  175. WHO Techn. Rep. Ser. No. 509 (1972): Treatment of heamoglobinopathies and allied disorders.Google Scholar
  176. WHO Techn. Rep. Ser. No. 524 (1973): Pharmacogenetics.Google Scholar
  177. Wolff, P.H.: Ethnic differences in alcohol sensitivity. Science 175, 449–450 (1972)Google Scholar
  178. Wolff, P.H.: Vasomotor sensitivity to alcohol in diverse mongoloid populations. Am. J. Hum. Genet. 25, 193–199 (1973)Google Scholar
  179. Zimmermann, A., Matschiner, J.T.: Biochemical basis of hereditary resistance to warfarin in the rat. Biochem. Pharmacol. 23, 1033–1040 (1974)Google Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • Peter Propping
    • 1
  1. 1.Institut für Anthropologie und Humangenetik der Universität HeidelbergHeidelberg

Personalised recommendations